Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Exploratory Clinical Study to Determine the Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict Gastrointestinal Radiation Toxicity Using Circulating Cell Free DNA Directly From Plasma

NCT04580667 is registered in ClinicalTrials.gov with DiaCarta, Inc. as lead sponsor.

NCT NCT04580667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04580667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Exploratory Clinical Study to Determine the Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict Gastrointestinal Radiation Toxicity Using Circulating Cell Free DNA Directly From Plasma
Lead sponsor
DiaCarta, Inc.
Phase
Observational
Overall status
Withdrawn
Start date
October 1, 2020
Completion date
September 6, 2023
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer